Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 8/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105902 | 1.00 | FOLH1 (0.56) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL55972 | 1.00 | FOLH1 (0.56) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| Methane SCHEMBL4610737 | 0.98 | FOLH1 (0.55) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL188399 | 0.91 | FOLH1 (0.49) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL188398 | 0.91 | FOLH1 (0.49) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL28520123 | 0.89 | FOLH1 (0.48) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL6037021 | 0.87 | FOLH1 (0.46) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| Carbamic Acid SCHEMBL7215414 | 0.87 | SLC7A5 (0.46) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| Sulfuric Acid SCHEMBL8910597 | 0.85 | MEN1 (0.48) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| Sulfuric Acid SCHEMBL8910593 | 0.85 | MEN1 (0.48) | FOLH1NAALAD2SLC7A5MMEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1921 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12546788-B2 | Methods for differentiating destructive thyroiditis from other pathological conditions | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2026-02-10 | — | — | US | claimed |
| CN-117554536-B | Simultaneous analysis method for 15 thyroid hormones in environmental water sample | 北京林业大学 | 2024-03-19 | — | — | CN | claimed |
| CN-117554536-A | Simultaneous analysis method for 15 thyroid hormones in environmental water sample | 北京林业大学 | 2024-02-13 | — | — | CN | claimed |
| WO-2023234809-A1 | METHOD FOR PREVENTING IODINE RADIONUCLIDE DAMAGE TO THE HUMAN OR ANIMAL BODY | АНДРЕЙЧУК, ВАСИЛИЙ ПЕТРОВИЧ | 2023-12-07 | — | — | WO | claimed |
| CN-116731104-A | Tumor high affinity peptide YQP-3 and application thereof | 中国药科大学 | 2023-09-12 | — | — | CN | claimed |
| US-20230168257-A1 | METHODS FOR DIFFERENTIATING DESTRUCTIVE THYROIDITIS FROM OTHER PATHOLOGICAL CONDITIONS | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-01 | — | — | US | claimed |
| US-11598759-B2 | Sensors and sensor arrays for detection of analytes | ICAGEN, LLC (US) | 2023-03-07 | — | — | US | claimed |
| EP-4130746-A1 | METHOD FOR DIFFERENTIATING DESTRUCTIVE THYROIDITIS FROM OTHER PATHOLOGICAL CONDITIONS | ASKA Pharmaceutical Co., Ltd. (JP) | 2023-02-08 | — | — | EP | claimed |
| CN-115398237-A | Method for distinguishing destructive thyroiditis from other pathological states | ASKA制药株式会社 | 2022-11-25 | — | — | CN | claimed |
| US-20220241323-A1 | METHOD FOR THE PRODUCTION OF IODINATED PROTEINS WITH A DETERMINATED IODINE CONTENT | "I2LIFE" LIMITED LIABILITY COMPANY ("I2LIFE" LLC) (RU) | 2022-08-04 | — | — | US | claimed |
| US-5690967-A | MIXTURE CONTAINING AMPHOTERIC AGENT | TRISTRATA TECHNOLOGY, INC. (US) | 1997-11-25 | — | — | US | claimed |
| US-5684044-A | MIXED WITH AMPHOTERIC OR PSEUDOAMPHOTERIC AGENT | TRISTRATA, INCORPORATED (US) | 1997-11-04 | — | — | US | claimed |
| WO-1997016201-A1 | ANGIOTENSIN IV AND ANALOGS AS REGULATORS OF FIBRINOLYSIS | BRIGHAM & WOMEN'S HOSPITAL (US) | 1997-05-09 | — | — | WO | claimed |
| EP-0413528-B1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | YU RUEY J (US) | 1995-11-15 | — | — | EP | claimed |
| EP-0649325-A4 | ADMINISTRATION OF MEDICAMENTS TO POULTRY. | SANOFI ANIMAL HEALTH INC (US) | 1995-08-23 | — | — | EP | claimed |
| EP-0649325-A1 | ADMINISTRATION OF MEDICAMENTS TO POULTRY | SANOFI ANIMAL HEALTH, Inc. (US) | 1995-04-26 | — | — | EP | claimed |
| US-5311841-A | Administration of medicaments of poultry | THAXTON, J. PAUL | 1994-05-17 | — | — | US | claimed |
| WO-1994001147-A2 | ADMINISTRATION OF MEDICAMENTS TO POULTRY | SANOFI ANIMAL HEALTH, INC. (US) | 1994-01-20 | — | — | WO | claimed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | claimed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12546788-B2 | Methods for differentiating destructive thyroiditis from other pathological conditions | TPO, TSHR, TH | FOLH1 1725/4885NAALAD2 1130/4885SLC7A5 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.